McCleane Gary
Rampark Pain Centre, 2 Rampark, Dromore Road, Lurgan BT66 7JH, Northern Ireland, UK.
CNS Drugs. 2003;17(14):1031-43. doi: 10.2165/00023210-200317140-00003.
In health, the nervous system exists in a balance between inhibitory and excitatory influences. This balance may be upset if neural tissue is damaged or irritated and may give rise to neuropathic pain. Such neuropathic pain does not respond consistently to opioid analgesics or NSAIDs and it may therefore be necessary to utilise other therapeutic agents with known activity on either the excitatory or inhibitory components of the pain pathway. These other agents are traditionally considered with reference to their original uses; we still refer to tricyclic antidepressants (TCAs) and anticonvulsant drugs when a consideration of their modes of action may allow more rational use. For example, carbamazepine is related to the TCAs by virtue of its chemical structure and proposed mode of action and yet is still classified as an anticonvulsant drug. With respect to the opioids, increasing evidence points to an analgesic effect in neuropathic pain, although concerns regarding tolerance and dependence still prevent more widespread use. The anticonvulsants comprise a group of compounds possessing anticonvulsant and analgesic properties, but each possesses differing modes of action and so several members of the class should be tried before a conclusion is reached that they, as a whole, are ineffective. TCAs may also have a role in the treatment of neuropathic pain. As with all drugs, if their use is not associated with pain relief in a defined period of time, their use should be terminated. Topical TCAs may also have a role where the area of neuropathic pain is small. Other options, such as SSRIs, membrane stabilisers, capsaicin, baclofen and clonidine may have potential in treating neuropathic pain. The available evidence regarding the efficacy of currently available agents for the treatment of neuropathic pain is sparse. With the knowledge of achieving analgesia, according to the modes of actions of various agents it is hoped that the treatment of this difficult condition may be more logical and successful.
在健康状态下,神经系统存在于抑制性和兴奋性影响之间的平衡中。如果神经组织受损或受到刺激,这种平衡可能会被打破,进而引发神经性疼痛。这种神经性疼痛对阿片类镇痛药或非甾体抗炎药的反应并不一致,因此可能有必要使用其他对疼痛通路的兴奋性或抑制性成分具有已知活性的治疗药物。传统上,这些其他药物是根据其最初用途来考虑的;当考虑它们的作用方式可能允许更合理使用时,我们仍然提及三环类抗抑郁药(TCA)和抗惊厥药物。例如,卡马西平因其化学结构和推测的作用方式与三环类抗抑郁药相关,但仍被归类为抗惊厥药物。关于阿片类药物,越来越多的证据表明其在神经性疼痛中有镇痛作用,尽管对耐受性和依赖性的担忧仍然阻碍了其更广泛的使用。抗惊厥药是一组具有抗惊厥和镇痛特性的化合物,但每种药物的作用方式不同,因此在得出它们整体无效的结论之前,应该尝试该类药物中的几种。三环类抗抑郁药在神经性疼痛的治疗中也可能有作用。与所有药物一样,如果在规定时间内使用它们没有带来疼痛缓解,就应该停止使用。如果神经性疼痛的区域较小,局部使用三环类抗抑郁药也可能有作用。其他选择,如选择性5-羟色胺再摄取抑制剂(SSRI)、膜稳定剂、辣椒素、巴氯芬和可乐定,在治疗神经性疼痛方面可能具有潜力。关于目前可用药物治疗神经性疼痛疗效的现有证据很少。鉴于对实现镇痛作用的了解,根据各种药物的作用方式,希望对这种难治性疾病的治疗可能会更具逻辑性且更成功。